Beximco Pharma currently produces more than 300 generic medicines which are available in well over 500 different presentations and the broad portfolio encompasses all key therapeutic categories including antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, dermatology, gastrointestinal etc.
Read More..

Life's all about staying healthy and enjoying the good things in life! However, illness is inevitable at all stages of life. In this area learn about the common health problems and how to deal with your and your family's illness.Read More

Welcome to the registered Health Professionals, to this exclusive Doctors only area. This provides you access to latest medical updates, events, guidelines and information relevant to your practice. If you are not a registered doctor please do not enter this area.Read More

As the company is incorporated in Bangladesh (not in UK), it is hereby stated that the rights of shareholders of the company may be different from the rights of shareholders in a UK incorporated company.Read More

Welcome to Beximco Pharma’s news and media center. Here in the media center you will find a range of resources including our latest and archived news releases, publication and information on our official social media, and multimedia gallery where our photo and video library.
Read More

Veniron

Iron-sucrose 100 mg/5ml

Injection

1. What Veniron® is and what it is used for?Veniron® is a brown, sterile, aqueous, complex of Polynuclear Iron (III) Hydroxide in Sucrose for Intravenous use. The drug product contains approximately 30% Sucrose w/v (300 mg/ml).

Veniron® is indicated for the treatment of Iron deficiency in the following indications:

Where there is a clinical need for a rapid Iron supply In patients who can not tolerate oral Iron therapy or who are non-compliant In active inflammatory bowel disease where oral Iron preparations are ineffective.

It is also indicated in the treatment of Iron deficiency anaemia in patients undergoing surgical procedures, patients donating blood, postpartum patients.

2. Before you take Veniron® The use of Iron Sucrose is contraindicated in patients with evidence of Iron overload, in patients with known hypersensitivity to Iron Sucrose or any of its inactive components, and in patients with anaemia not caused by Iron deficiency. It is also contraindicated in patients with history of allergic disorders including asthma, eczema and anaphylaxis, liver disease and infections.

Take special care with Veniron® Check with your doctor before taking this medicine if: General: Because body Iron excretion is limited and excess tissue Iron can be hazardous, caution should be exercised to withhold Iron administration in the presence of evidence of tissue Iron overload. Patients receiving Iron Sucrose require periodic monitoring of hematologic and haematinic parameters (hemoglobin, hematocrit, serum ferritin and transferrin saturation). Iron therapy should be withheld in patients with evidence of Iron overload. Transferrin saturation values increase rapidly after IV administration of Iron Sucrose; thus, serum Iron values may be reliably obtained 48 hours after IV dosing. Hypersensitivity Reactions: Serious hypersensitivity reactions have been rarely reported in patients receiving Iron Sucrose. Several cases of mild or moderate hypersensitivity reactions were observed in these studies.

Hypotension: Hypotension has been reported frequently in hemodialysis patients receiving intravenous Iron. Hypotension following administration of Iron Sucrose may be related to rate of administration and total dose administered. Caution should be taken to administer Iron Sucrose according to recommended guidelines.

Pediatric Use: Safety and effectiveness of Iron Sucrose in pediatric patients have not been established.

Geriatric Use: No overall differences in safety were observed between the elder subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Taking other medicines Drug-drug interactions involving Iron Sucrose have not been studied. Iron Sucrose Injection should not be administered concomitantly with oral iron preparations since the absorption of oral Iron is reduced. Even oral Iron therapy should not be given until 5 days after last injection.

Pregnancy and breast-feeding

Use in Pregnancy: Pregnancy Category-B. No adequate and well controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed.

Use in Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Iron Sucrose is administered to a nursing woman.

3. How to take Veniron®? Veniron® is exclusively to be administered intravenously by drip infusion, by slow injection or directly into the venous limb of the dialyser and is not suitable for intramuscular use and for total dose infusion (TDI), where the full dose of Iron required, representing the patient's total Iron deficit is administered in one complete infusion. Before administration of the first therapeutic dose, a test dose should be given.

Dosage and administration Normal Dosage Adults and Elderly: 5-10 ml Veniron® (100-200 mg Iron) once to three times a week depending on the hemoglobin level. Children: There is limited data on children under study conditions. If there is a clinical need, it is recommended not to exceed 0.15 ml Veniron® (3 mg Iron) per kg body weight once to three times per week depending on the haemoglobin level.